MannKind Corporation

Valuation Analysis

About the Company

MannKind Corporation en bref

MannKind Corporation (MNKD) is currently trading at 3,39 € with a market capitalization of 1,0 Md €. The 52-week range spans from 1,93 € to 5,64 €; the current price is 39.9% below the yearly high. Year-over-year revenue growth stands at +15.1%.

💰 Dividende

MannKind Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

8 analystes évaluent MannKind Corporation (MNKD) au consensus : Achat Fort. L'objectif de cours moyen est de 6,69 €, soit un potentiel de +97.41% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 4,12 € à 9,54 €.

MannKind Corporation : la thèse d'investissement en détail

MannKind Corporation (MNKD) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 15.1% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 75.63%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 97.41% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valorisation en contexte

At a PEG of 4.39, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 42.7x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The analyst consensus price target implies 97.41% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to market-like volatility, elevated short interest (9.25%).

Trading Data

Related Stocks in the Same Sector

Where can I buy MannKind Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.